Meeting NewsVideo

VIDEO: Real-world results alleviate medical community concerns about LAA occlusion device

WASHINGTON — In this video, Patrick T. O’Gara, MD, MACC, past president of the American College of Cardiology and director of clinical cardiology and executive medical director, Shapiro Cardiovascular Center, at Brigham and Women’s Hospital, discusses the results of a registry of a left atrial appendage occlusion device (Watchman, Boston Scientific) for stroke prevention in patients with nonvalvular atrial fibrillation presented at TCT 2016.

According to O’Gara, the complexity the implantation procedure and the inexperience of operators implanting the device has been a cause for concern in the medical community. However, he said, the study showed low rates of major complications, including pericardial tamponade, device migration and procedure-related death.

“I think this is a very important addition to our understanding of where these devices might fit in in the spectrum of interventions that we can apply to patients who have AF and who are at risk of stroke or systemic embolism,” he said.

 

 

 

WASHINGTON — In this video, Patrick T. O’Gara, MD, MACC, past president of the American College of Cardiology and director of clinical cardiology and executive medical director, Shapiro Cardiovascular Center, at Brigham and Women’s Hospital, discusses the results of a registry of a left atrial appendage occlusion device (Watchman, Boston Scientific) for stroke prevention in patients with nonvalvular atrial fibrillation presented at TCT 2016.

According to O’Gara, the complexity the implantation procedure and the inexperience of operators implanting the device has been a cause for concern in the medical community. However, he said, the study showed low rates of major complications, including pericardial tamponade, device migration and procedure-related death.

“I think this is a very important addition to our understanding of where these devices might fit in in the spectrum of interventions that we can apply to patients who have AF and who are at risk of stroke or systemic embolism,” he said.

 

 

 

    See more from TCT